Duopharma Biotech Berhad

KLSE:DPHARMA Stock Report

Market Cap: RM 1.2b

Duopharma Biotech Berhad Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Leonard bin Abdul Shatar

Chief executive officer

RM 2.4m

Total compensation

CEO salary percentage52.7%
CEO tenure17.3yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be Increased To MYR0.02

Feb 24
Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be Increased To MYR0.02

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17
Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21
These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18
Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07
Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28
Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27
Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26
We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25
Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20
Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22
Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13
Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 14
A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Feb 12
Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Jan 28
Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

CEO Compensation Analysis

How has Leonard bin Abdul Shatar's remuneration changed compared to Duopharma Biotech Berhad's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024RM 2mRM 1m

RM 63m

Sep 30 2024n/an/a

RM 56m

Jun 30 2024n/an/a

RM 49m

Mar 31 2024n/an/a

RM 45m

Dec 31 2023RM 3mRM 1m

RM 53m

Sep 30 2023n/an/a

RM 61m

Jun 30 2023n/an/a

RM 69m

Mar 31 2023n/an/a

RM 72m

Dec 31 2022RM 2mRM 1m

RM 70m

Sep 30 2022n/an/a

RM 69m

Jun 30 2022n/an/a

RM 69m

Mar 31 2022n/an/a

RM 68m

Dec 31 2021RM 2mRM 1m

RM 66m

Sep 30 2021n/an/a

RM 66m

Jun 30 2021n/an/a

RM 63m

Mar 31 2021n/an/a

RM 63m

Dec 31 2020RM 2mRM 924k

RM 59m

Sep 30 2020n/an/a

RM 54m

Jun 30 2020n/an/a

RM 55m

Mar 31 2020n/an/a

RM 54m

Dec 31 2019RM 2mRM 882k

RM 55m

Sep 30 2019n/an/a

RM 58m

Jun 30 2019n/an/a

RM 55m

Mar 31 2019n/an/a

RM 51m

Dec 31 2018RM 1mRM 876k

RM 48m

Compensation vs Market: Leonard's total compensation ($USD574.12K) is above average for companies of similar size in the MY market ($USD114.62K).

Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.

CEO

Leonard bin Abdul Shatar (59 yo)

17.3yrs

Tenure

RM 2,449,300

Compensation

Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...

Leadership Team

NamePositionTenureCompensationOwnership
Ariff bin Abdul Shatar
Group MD & Executive Director17.3yrsRM 2.45mno data
Wu Chek
Chief Financial Officer12.8yrsno data0.000010%
MYR 119.3
Wan Bin Wan Abdul Majid
Chief Executive Officer of Group Operationsless than a yearno datano data
Ibrahim Salleh
Chief Legal Officer & Group Company Secretary7.4yrsno datano data
Sabrina Binti Haron
Chief Compliance Officer1.8yrsno datano data
Krisnakumara Reddi
Chief Manufacturing & Sustainability Officer2.6yrsno data0.00030%
MYR 3.6k
Shamsul Bin A. Iahad
Chief Consumer Healthcare Officerless than a yearno datano data
Wan Ahmad Bin Wan Mohd. Salleh
Group Head of Risk Management & Integrity2.3yrsno datano data
Priya Asokan
Chief Innovation Officerless than a yearno datano data

2.3yrs

Average Tenure

52yo

Average Age

Experienced Management: DPHARMA's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ariff bin Abdul Shatar
Group MD & Executive Director7.4yrsRM 2.45mno data
Nik Binti Nik Mohamed Shihabuddin
Independent Non-Executive Directorless than a yearRM 72.80kno data
Razalee Bin Amin
Independent Non-Executive Director8.9yrsRM 151.10kno data
Mohd Bin Mohd Yunus
Non Independent Non Executive Director7.2yrsRM 145.80k0%
MYR 0
Nik Bin Nik Hassan
Independent Non-Executive Director7.4yrsRM 145.20kno data
Zaki Bin Mohamad Zaher
Independent Non-Executive Director5.7yrsRM 139.40kno data
Zaiton Binti Jamaluddin
Independent Non Executive Director8.7yrsRM 158.60kno data
Eisah Binti Rahman
Senior Independent Non-Executive Director8.5yrsRM 140.30kno data
Kartini Binti Hj Abdul Manaf
Non-Independent & Non-Executive Chairman1.9yrsRM 137.50kno data
Muhammad Bin Ismail
Alternate Directorno datano datano data
Mohd Bin Mohd Arshad
Non-Independent & Non-Executive Director1.2yrsRM 108.60kno data

7.3yrs

Average Tenure

64yo

Average Age

Experienced Board: DPHARMA's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 10:24
End of Day Share Price 2025/05/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Duopharma Biotech Berhad is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Cheng Wei LewCGS International
Ping-Khoon ChooKenanga Research
Kenneth LeongMalacca Securities Sdn Bhd